Blood-aqueous Barrier Integrity in Eyes Undergoing Intravitreal Bevacizumab Therapy to Treat Neovascular AMD

Sponsor
Medical University of Lublin
Study ID
NCT03744806
Status
Completed

Conditions

  • Exudative Age-related Macular Degeneration

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The aim of this study is to evaluate the effect of repeated intravitreal bevacizumab injections on blood-aqueous barrier permeability in eyes with neovascular age-related macular degeneration (AMD).

Key Dates

First listed
Nov 16, 2018
Start date
Jan 31, 2015
Status verified
Nov 2018
Primary completion
Sep 30, 2015
Completion
Aug 31, 2018

Study Design

Enrollment
48 participants (actual)

Arms

  • Arm: treated with intravitreal bevacizumab.
  • Arm: control group

Primary Outcome Measure

Anterior chamber (AC) inflammation evaluated with laser flare photometry. [ Time Frame: 4 months ]